Medtech And US DoJ: EpiPen, Dermagraft Lead 2017 Payouts To Feds
Executive Summary
US DoJ collected more than $1bn in penalties from device manufacturers this year, chiefly on false claims and manufacturing violations. Here is a roundup and sortable table of the payouts.
You may also be interested in...
Pfizer Settles $345M EpiPen Consumers Suit, But Viatris Marches On
After four years of litigation, Pfizer has reached a preliminary settlement over allegations that it devised an “illegal scheme” with Viatris’ Mylan establish a monopoly for the EpiPen autoinjector device.
Former ArthroCare CFO Gets 50 Months In Prison
Michael Gluk, who participated in a scheme to falsely inflate ArthroCare’s earnings by parking unsold merchandise with distributors, pleaded guilty to one count of conspiracy to commit wire and securities fraud after his initial conviction was overturned.
Shire To Pay Record-Setting Device FCA Settlement
The $350m settlement resolves False Claims Act allegations Shire and its subsidiaries used tactics including lavish meals, free medical equipment, unearned speaker payments and cash to encourage doctors to prescribe the company’s Dermagraft human skin substitute.